Solid Biosciences (SLDB) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Solid Biosciences insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $2.7M of SLDB stock on the open market.
Get emailed when insiders cluster-buy stocks like SLDB
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SLDB insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $2.5M | 22 |
| Q4 2025 | — | 0 | $148K | 6 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Solid Biosciences Inc. insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $2.7M. 26 of 29 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Feb 18SEC | Alexander CumboCEO, President | Sell Plan | 16,644235,405 held (−7%) | $5.82 | $97K | +18.0% | — |
| Feb 18SEC | David T HowtonCOO | Sell Plan | 7,469105,077 held (−7%) | $5.82 | $43K | +18.0% | — |
| Feb 18SEC | Kevin TanCFO | Sell Plan | 5,40499,422 held (−5%) | $5.82 | $31K | +18.0% | — |
| Feb 18SEC | Jessie HanrahanChief Regulatory Officer | Sell Plan | 4,13474,318 held (−5%) | $5.82 | $24K | +18.0% | — |
| Feb 18SEC | Paul HerzichCTO | Sell Plan | 3,61672,638 held (−5%) | $5.82 | $21K | +18.0% | — |
| Feb 18SEC | Ilan GanotDirector | Sell Plan | 2,65827,474 held (−9%) | $5.82 | $15K | +18.0% | — |
| Feb 18SEC | Gabriel BrooksChief Medical Officer | Sell Plan | 089,466 held (−0%) | $5.82 | $0 | +18.0% | — |
| Feb 6SEC | Alexander CumboCEO, President | Sell Plan | 48,913222,018 held (−18%) | $6.44 | $315K | +6.7% | — |
| Feb 6SEC | David T HowtonCOO | Sell Plan | 18,89497,859 held (−16%) | $6.44 | $122K | +6.7% | — |
| Feb 6SEC | Kevin TanCFO | Sell Plan | 14,78394,201 held (−14%) | $6.44 | $95K | +6.7% | — |
| Feb 6SEC | Gabriel BrooksChief Medical Officer | Sell Plan | 12,61684,092 held (−13%) | $6.44 | $81K | +6.7% | — |
| Feb 6SEC | Jessie HanrahanChief Regulatory Officer | Sell Plan | 12,34870,327 held (−15%) | $6.44 | $80K | +6.7% | — |
| Feb 6SEC | Paul HerzichCTO | Sell Plan | 10,90569,067 held (−14%) | $6.44 | $70K | +6.7% | — |
| Feb 6SEC | Ilan GanotDirector | Sell Plan | 7,20525,271 held (−22%) | $6.44 | $46K | +6.7% | — |
| Feb 2SEC | Alexander CumboCEO, President | Sell Plan | 80,258270,931 held (−23%) | $6.44 | $517K | +6.7% | — |
| Feb 2SEC | David T HowtonCOO | Sell Plan | 37,771116,753 held (−24%) | $6.44 | $243K | +6.7% | — |
| Feb 2SEC | Gabriel BrooksChief Medical Officer | Sell Plan | 28,33596,708 held (−23%) | $6.44 | $182K | +6.7% | — |
| Feb 2SEC | Kevin TanCFO | Sell Plan | 26,837108,984 held (−20%) | $6.44 | $173K | +6.7% | — |
| Feb 2SEC | Jessie HanrahanChief Regulatory Officer | Sell Plan | 26,53582,675 held (−24%) | $6.44 | $171K | +6.7% | — |
| Feb 2SEC | Paul HerzichCTO | Sell Plan | 26,25079,972 held (−25%) | $6.44 | $169K | +6.7% | — |
| Jan 30SEC | Ilan GanotDirector | Sell Plan | 19117,476 held (−1%) | $6.59 | $1K | +4.2% | — |
| Jan 13SEC | Kevin TanCFO | Sell Plan | 5,70446,100 held (−11%) | $5.27 | $30K | +30.4% | — |
| Jan 6SEC | Ilan GanotDirector | Sell | 1,05317,278 held (−6%) | $5.43 | $6K | +26.5% | — |
| Dec 4SEC | Alexander CumboCEO, President | Sell Plan | 10,80881,388 held (−12%) | $5.11 | $55K | +34.4% | — |
| Dec 4SEC | David T HowtonCOO | Sell Plan | 4,93232,908 held (−13%) | $5.11 | $25K | +34.4% | — |
| Dec 4SEC | Jessie HanrahanChief Regulatory Officer | Sell Plan | 4,48326,660 held (−14%) | $5.11 | $23K | +34.4% | — |
| Dec 4SEC | Paul HerzichCTO | Sell Plan | 2,70126,622 held (−9%) | $5.11 | $14K | +34.4% | — |
| Nov 13SEC | Ilan GanotDirector | Sell | 3,27895,412 held (−3%) | $4.12 | $14K | +66.7% | — |
| Oct 21SEC | Gabriel BrooksChief Medical Officer | Sell | 2,89533,819 held (−8%) | $5.96 | $17K | +15.3% | — |
Insiders at Solid Biosciences Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Alexander CumboCEO, President | — | $984K | Feb 18, 2026 | — |
| David T HowtonCOO | — | $434K | Feb 18, 2026 | — |
| Kevin TanCFO | — | $330K | Feb 18, 2026 | — |
| Jessie HanrahanChief Regulatory Officer | — | $297K | Feb 18, 2026 | — |
| Gabriel BrooksChief Medical Officer | — | $281K | Feb 18, 2026 | — |
| Paul HerzichCTO | — | $274K | Feb 18, 2026 | — |
| Ilan GanotDirector | — | $82K | Feb 18, 2026 | — |
SLDB stock: common questions
Are Solid Biosciences Inc. insiders buying SLDB stock?
In the past 12 months, 0 insiders reported open-market purchases of SLDB worth $0.
Are Solid Biosciences Inc. insiders selling SLDB stock?
7 insiders reported sales worth $2.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SLDB's 52-week range?
Over the past year SLDB has traded between $3.93 and $11.15. It last closed at $6.87 on Oct 9, 2026.